JP6727425B2 - 抗ｃｄ２７抗体 - Google Patents

抗ｃｄ２７抗体 Download PDF

Info

Publication number
JP6727425B2
JP6727425B2 JP2019515807A JP2019515807A JP6727425B2 JP 6727425 B2 JP6727425 B2 JP 6727425B2 JP 2019515807 A JP2019515807 A JP 2019515807A JP 2019515807 A JP2019515807 A JP 2019515807A JP 6727425 B2 JP6727425 B2 JP 6727425B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535235A (ja
Inventor
ビービ，エイミー・エム
チェン，ジャイソン・カ・ジェン
ジュアン，ベロニカ
フェイアダット‐ディルマン，ローレンス
サディコワ，スヴェトラーナ
ワン，ジェリリン
フィッシュマン，ティエリー・オリヴァー
プロサイス，ウィニフレッド・ダブリュー
バン・エネナーム，ハンス
バン・エルザ，アンドレア
ギュレン，ラース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2019535235A publication Critical patent/JP2019535235A/ja
Application granted granted Critical
Publication of JP6727425B2 publication Critical patent/JP6727425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019515807A 2016-09-26 2017-09-25 抗ｃｄ２７抗体 Active JP6727425B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662399837P 2016-09-26 2016-09-26
US62/399,837 2016-09-26
US201762546214P 2017-08-16 2017-08-16
US62/546,214 2017-08-16
PCT/US2017/053204 WO2018058022A1 (en) 2016-09-26 2017-09-25 Anti-cd27 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020062240A Division JP7002588B2 (ja) 2016-09-26 2020-03-31 抗ｃｄ２７抗体

Publications (2)

Publication Number Publication Date
JP2019535235A JP2019535235A (ja) 2019-12-12
JP6727425B2 true JP6727425B2 (ja) 2020-07-22

Family

ID=60002145

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019515807A Active JP6727425B2 (ja) 2016-09-26 2017-09-25 抗ｃｄ２７抗体
JP2020062240A Active JP7002588B2 (ja) 2016-09-26 2020-03-31 抗ｃｄ２７抗体
JP2021212448A Withdrawn JP2022046684A (ja) 2016-09-26 2021-12-27 抗ｃｄ２７抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020062240A Active JP7002588B2 (ja) 2016-09-26 2020-03-31 抗ｃｄ２７抗体
JP2021212448A Withdrawn JP2022046684A (ja) 2016-09-26 2021-12-27 抗ｃｄ２７抗体

Country Status (26)

Country Link
US (3) US10556957B2 (enExample)
EP (1) EP3515941A1 (enExample)
JP (3) JP6727425B2 (enExample)
KR (2) KR102237921B1 (enExample)
CN (2) CN117924486A (enExample)
AR (1) AR109715A1 (enExample)
AU (3) AU2017331380C1 (enExample)
BR (1) BR112019005726A8 (enExample)
CA (1) CA3036573C (enExample)
CL (2) CL2019000779A1 (enExample)
CO (1) CO2019002671A2 (enExample)
CR (1) CR20190140A (enExample)
DO (1) DOP2019000077A (enExample)
EC (1) ECSP19020740A (enExample)
GE (1) GEP20217263B (enExample)
IL (2) IL265434B2 (enExample)
JO (1) JOP20190055A1 (enExample)
MA (1) MA46272A (enExample)
MX (2) MX392779B (enExample)
MY (1) MY197866A (enExample)
NI (1) NI201900024A (enExample)
PE (1) PE20190737A1 (enExample)
PH (1) PH12019500628A1 (enExample)
TN (1) TN2019000075A1 (enExample)
TW (2) TWI854952B (enExample)
WO (1) WO2018058022A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022046684A (ja) * 2016-09-26 2022-03-23 メルク・シャープ・アンド・ドーム・コーポレーション 抗ｃｄ２７抗体

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
PL3212670T3 (pl) 2014-10-29 2021-06-14 Five Prime Therapeutics, Inc. Leczenie skojarzone nowotworów
CN111479586A (zh) * 2017-09-13 2020-07-31 戊瑞治疗有限公司 用于胰腺癌的组合抗csf1r和抗pd-1抗体的组合疗法
JP7680208B2 (ja) * 2018-04-04 2025-05-20 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ２７抗体およびその使用
US11795230B2 (en) 2018-04-13 2023-10-24 Dingfu Biotarget Co., Ltd. Anti-CD27 antibodies and use thereof
KR20210011919A (ko) * 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
EP3820904A2 (en) 2018-07-09 2021-05-19 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
AU2020372912A1 (en) * 2019-11-01 2022-05-26 Merck Sharp & Dohme Llc Dosing regimen of anti-CD27 antibodies for treatment of cancer
EP4069745A4 (en) * 2019-11-06 2024-05-29 The Regents Of The University Of California Compositions and methods for transferrin receptor 1 targeting
JP2023535610A (ja) * 2020-07-28 2023-08-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンを予防及び処置するための方法及び組成物
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
TW202328192A (zh) 2021-09-06 2023-07-16 荷蘭商珍美寶公司 能結合ｃｄ２７之抗體、彼之變異體及彼等之用途
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
CN114014928B (zh) * 2021-10-27 2023-05-12 南京安吉生物科技有限公司 抗hmmw抗体、包含该抗体的组合物、编码该抗体的核酸分子及其用途
CN119451985A (zh) 2022-05-12 2025-02-14 健玛保 在组合疗法中能够结合cd27的结合剂
US20250325643A1 (en) 2022-05-12 2025-10-23 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
CN118667002A (zh) * 2023-03-16 2024-09-20 上海赛金生物医药有限公司 抗cd27单克隆抗体及其应用
CN118684778B (zh) * 2024-08-27 2024-11-08 天津旷博同生生物技术有限公司 一种抗人cd27抗体及应用

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5229289A (en) 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5420245A (en) 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0604181A1 (en) 1992-12-21 1994-06-29 Eli Lilly And Company Antitumor compositions and method of treatment
WO1994019357A1 (en) 1993-02-23 1994-09-01 Merrell Dow Pharmaceuticals Inc. Farnesyl:protein transferase inhibitors as anticancer agents
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
EP0698015A1 (en) 1993-05-14 1996-02-28 Genentech, Inc. Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
US5602098A (en) 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
WO1995008542A1 (en) 1993-09-22 1995-03-30 Kyowa Hakko Kogyo Co., Ltd. Farnesyltransferase inhibitor
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
IL111257A0 (en) 1993-10-15 1994-12-29 Schering Corp Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
AU699043B2 (en) 1993-10-15 1998-11-19 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
DK0725790T3 (da) 1993-10-25 2001-06-11 Parke Davis & Co Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
DE69417012T2 (de) 1993-11-04 1999-10-07 Abbott Laboratories, Abbott Park Cyclobutan-derivate als inhibitoren der squalen-synthetase und der protein-farnesyltransferase
FI961819A7 (fi) 1993-11-05 1996-04-29 Warner Lambert Co Proteiini:farnesyylitransferaasin substituoidut di- ja tripeptidi-inhi biittorit
US5484799A (en) 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
WO1995024612A1 (de) 1994-03-07 1995-09-14 International Business Machines Corporation Verfahren und vorrichtung zur schnellen interpolation von zwischenwerten aus periodischen phasenverschobenen signalen und zur erkennung von defekten in einem drehkörper
CN1151156A (zh) 1994-03-15 1997-06-04 卫材株式会社 异戊二烯基转移酶抑制剂
IL113196A0 (en) 1994-03-31 1995-06-29 Bristol Myers Squibb Co Imidazole derivatives and pharmaceutical compositions containing the same
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US5510510A (en) 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US5563255A (en) 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
CZ361996A3 (en) 1994-06-10 1997-04-16 Rhone Poulenc Rorer Sa Inhibitors of farnesyl-transferase, process of their preparation and pharmaceutical compositions containing thereof
US5571792A (en) 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
WO1996005529A1 (en) 1994-08-09 1996-02-22 Micron Optics, Inc. Temperature compensated fiber fabry-perot filters
ATE188464T1 (de) 1994-08-11 2000-01-15 Banyu Pharma Co Ltd Substituierte amidderivate
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
WO1996005169A1 (en) 1994-08-12 1996-02-22 Banyu Pharmaceutical Co., Ltd. N,n-disubstituted amic acid derivative
DE4429506B4 (de) 1994-08-19 2007-09-13 Degussa Gmbh Verfahren zur Extraktion natürlicher Carotinoid-Farbstoffe
DE4429653C2 (de) 1994-08-20 1997-04-03 Anton Dr More Konverter und Verfahren zum Frischen von Metallschmelzen insbesondere von Roheisen zu Stahl
JP4319251B2 (ja) 1994-11-22 2009-08-26 エヌエックスピー ビー ヴィ 半導体素子を有し導体トラックが形成されている基板が接着層により結合されている支持本体を有する半導体装置
AU3971295A (en) 1994-12-09 1996-06-26 Warner-Lambert Company Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
WO1996021701A2 (en) 1995-01-09 1996-07-18 Magla International Ltd. Wear resistant image printing on latex surfaces
AU4915796A (en) 1995-01-12 1996-07-31 University Of Pittsburgh Inhibitors of prenyl transferases
FR2729390A1 (fr) 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730492B1 (fr) 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730491B1 (fr) 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5700806A (en) 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5684013A (en) 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5891872A (en) 1995-04-07 1999-04-06 Schering Corporation Tricyclic compounds
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
AU5432696A (en) 1995-04-07 1996-10-23 Pharmacopeia, Inc. Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5831115A (en) 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
IL118101A0 (en) 1995-05-03 1996-09-12 Abbott Lab Inhibitors of farnesyltransferase
US5919780A (en) 1995-06-16 1999-07-06 Warner Lambert Company Tricyclic inhibitors of protein farnesyltransferase
FR2736641B1 (fr) 1995-07-10 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
AT402617B (de) 1995-07-11 1997-07-25 Datacon Schweitzer & Zeindl Gm Anlage zum automatisierten, hermetischen anlage zum automatisierten, hermetischen verschliessen von gehäusen verschliessen von gehäusen
FR2736638B1 (fr) 1995-07-12 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
CH690163A5 (fr) 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
CA2235986C (en) 1995-11-06 2006-09-12 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
ES2206607T3 (es) 1995-11-17 2004-05-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Derivados de epotilones, preparacion y utilizacion.
EP0862435A4 (en) 1995-11-22 1999-02-03 Merck & Co Inc Inhibitors of farnesyl-protein transferase
EA000710B1 (ru) 1995-12-08 2000-02-28 Жансен Фармасетика Н.В. (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
IL125062A (en) 1995-12-22 2003-11-23 Schering Corp Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases
US6008372A (en) 1996-01-16 1999-12-28 Warner-Lambert Company Substituted dinaphthylmethyl and diheteroarylmethylacetyl histidine inhibitors of protein farnesyltransferase
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
WO1997038665A2 (en) 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
IL126833A0 (en) 1996-05-22 1999-08-17 Warner Lambert Co Inhibitors of protein farnesyl transferase
CA2260216A1 (en) 1996-07-15 1998-01-22 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CA2276150A1 (en) 1996-12-30 1998-07-09 Steven D. Young Inhibitors of farnesyl-protein transferase
JP2002511054A (ja) 1996-12-30 2002-04-09 メルク エンド カンパニー インコーポレーテッド ファルネシル蛋白トランスフェラーゼ阻害薬
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
US20030035790A1 (en) 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
JP2002536968A (ja) 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的な抗体およびその使用
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
ATE309385T1 (de) 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
CA2442264A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. A method of treating cancer
WO2002083140A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
AU2002252614B2 (en) 2001-04-10 2006-09-14 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AU2002251266A1 (en) 2001-04-10 2002-10-28 Merck Sharp And Dohme Limited Inhibitors of akt activity
CA2455365C (en) 2001-08-03 2014-07-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003039460A2 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1551812B1 (en) 2001-12-06 2009-03-04 Merck & Co., Inc. Mitotic kinesin inhibitors
DE60222302T2 (de) 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1481077B1 (en) 2001-12-06 2009-11-04 Merck & Co., Inc. Mitotic kinesin inhibitors
US7244723B2 (en) 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
JP4451136B2 (ja) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
WO2003084473A2 (en) 2002-04-08 2003-10-16 Merck & Co., Inc. Method of treating cancer
CA2481229C (en) 2002-04-08 2010-09-21 Merck & Co., Inc. Substituted pyrazine inhibitors of akt
AU2003226271B2 (en) 2002-04-08 2007-10-18 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of Akt activity
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
CA2485343A1 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
PL374190A1 (en) 2002-06-14 2005-10-03 Merck & Co, Inc. Mitotic kinesin inhibitors
EP1515949B1 (en) 2002-06-14 2007-03-14 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1575504A4 (en) 2002-08-01 2009-11-04 Us Gov Health & Human Serv METHOD FOR THE TREATMENT OF INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF THE CPG OLIGONUCLEOTIDES
CA2500848A1 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors
US7399764B2 (en) 2002-10-30 2008-07-15 Merck & Co., Inc. Inhibitors of Akt activity
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
JP2006515171A (ja) 2002-12-06 2006-05-25 ファルマシア コーポレイション ミトコンドリア膜に由来するミトｎｅｅｔポリペプチド、そのモジュレーター、及び該ミトｎｅｅｔポリペプチドの使用方法
WO2004058700A2 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2509212A1 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1578419A4 (en) 2002-12-30 2008-11-12 3M Innovative Properties Co IMMUNOSTIMULATING COMBINATIONS
EP1622616B1 (en) 2003-04-24 2011-06-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2004233827B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
DE602004023838D1 (de) 2003-04-24 2009-12-10 Merck & Co Inc Hemmer der akt aktivität
CA2522262A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
CA2686618A1 (en) 2003-07-17 2005-01-17 At&T Corp. Method and apparatus for windowing in entropy encoding
KR100536215B1 (ko) 2003-08-05 2005-12-12 삼성에스디아이 주식회사 플라즈마 디스플레이 패널
US7307085B2 (en) 2003-08-13 2007-12-11 Merck & Co., Inc. Mitotic kinesin inhibitors
AR045342A1 (es) 2003-08-15 2005-10-26 Merck & Co Inc Inhibidores de quinesina mitotica
AU2004266629B2 (en) 2003-08-15 2009-11-26 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
EP1656133A4 (en) 2003-08-15 2008-10-29 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
CA2534065A1 (en) 2003-08-15 2005-03-03 Paul J. Coleman Dihydropyrrole derivatives as mitotic kinesin inhibitors
US7294640B2 (en) 2004-02-06 2007-11-13 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2007532551A (ja) 2004-04-09 2007-11-15 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害剤
ATE499364T1 (de) 2004-04-09 2011-03-15 Merck Sharp & Dohme Hemmer der akt aktivität
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
WO2006014679A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
KR101625961B1 (ko) 2006-09-08 2016-05-31 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
EP2090320A1 (en) 2008-02-15 2009-08-19 Helmholtz-Zentrum für Infektionsforschung GmbH Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof
JP5425775B2 (ja) 2008-06-30 2014-02-26 協和発酵キリン株式会社 抗ｃｄ２７抗体
AU2010263272C1 (en) 2009-06-24 2016-02-11 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
JP6077856B2 (ja) * 2009-11-04 2017-02-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 操作型抗ｔｓｌｐ抗体本出願は、米国特許仮出願第６１／２９７，００８号（２０１０年１月２１日出願）、および米国特許仮出願第６１／２５８，０５１号（２００９年１１月４日出願）の利益を主張し、該仮出願は各々、引用によりその全体が本明細書に組み込まれる。
CA2785964C (en) 2009-12-29 2021-03-30 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
AU2013203270B2 (en) 2010-04-13 2016-05-19 Celldex Therapeutics Inc. Antibodies that bind human CD27 and uses thereof
CN103154034B (zh) * 2010-04-13 2016-06-08 塞尔德克斯医疗公司 结合人cd27的抗体及其用途
EP2591001B1 (en) * 2010-07-09 2021-11-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to cd27
WO2012019041A2 (en) 2010-08-04 2012-02-09 Duke University Regulatory b cells and their uses
EP2619571A4 (en) 2010-09-22 2014-03-26 The Feinstein Inst Medical Res HUMAN B1 CELLS AND APPLICATIONS THEREOF
US9132281B2 (en) 2011-06-21 2015-09-15 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
SG10201800158XA (en) 2011-09-22 2018-02-27 Amgen Inc Cd27l antigen binding proteins
JO3787B1 (ar) * 2012-03-15 2021-01-31 Janssen Biotech Inc أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها
CA3169263A1 (en) * 2012-11-13 2014-05-22 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
US9725494B2 (en) 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
MX2016000750A (es) 2013-08-02 2016-08-05 Aduro Biotech Holdings Europe B V Combinacion de agonistas de cd27 e inhibicion del punto de control inmunologico para estimulacion del sistema inmunologico.
AU2015237864B2 (en) 2014-03-24 2020-12-03 Cancer Research Technology Limited Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
JOP20190055A1 (ar) * 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022046684A (ja) * 2016-09-26 2022-03-23 メルク・シャープ・アンド・ドーム・コーポレーション 抗ｃｄ２７抗体

Also Published As

Publication number Publication date
KR102237921B1 (ko) 2021-04-13
JP7002588B2 (ja) 2022-01-20
KR20190053949A (ko) 2019-05-20
JP2020114241A (ja) 2020-07-30
TW201815824A (zh) 2018-05-01
IL312160A (en) 2024-06-01
WO2018058022A1 (en) 2018-03-29
AU2024227495A1 (en) 2024-11-14
BR112019005726A2 (pt) 2020-06-23
MX2022007522A (es) 2022-07-19
JOP20190055A1 (ar) 2019-03-24
AU2017331380C1 (en) 2021-06-03
GEP20217263B (en) 2021-06-10
AU2021200984A1 (en) 2021-03-11
US20180086841A1 (en) 2018-03-29
JP2019535235A (ja) 2019-12-12
MX2019003405A (es) 2019-05-30
US20190300618A1 (en) 2019-10-03
TWI854952B (zh) 2024-09-11
IL265434A (en) 2019-05-30
AR109715A1 (es) 2019-01-16
EP3515941A1 (en) 2019-07-31
MX392779B (es) 2025-03-24
AU2021200984B2 (en) 2024-08-01
CA3036573C (en) 2023-01-03
CN109890846A (zh) 2019-06-14
NI201900024A (es) 2019-05-27
AU2017331380B2 (en) 2020-12-03
KR102414485B1 (ko) 2022-06-28
TN2019000075A1 (en) 2020-07-15
CO2019002671A2 (es) 2019-03-29
CN109890846B (zh) 2023-10-24
US20200131272A1 (en) 2020-04-30
TW202504923A (zh) 2025-02-01
CN117924486A (zh) 2024-04-26
AU2017331380A1 (en) 2019-03-28
IL265434B1 (en) 2024-05-01
PE20190737A1 (es) 2019-05-23
PH12019500628A1 (en) 2019-08-05
MA46272A (fr) 2019-07-31
KR20210040465A (ko) 2021-04-13
CA3036573A1 (en) 2018-03-29
MY197866A (en) 2023-07-21
CR20190140A (es) 2019-05-17
DOP2019000077A (es) 2019-06-30
IL265434B2 (en) 2024-09-01
CL2021000088A1 (es) 2021-07-02
ECSP19020740A (es) 2019-04-30
JP2022046684A (ja) 2022-03-23
BR112019005726A8 (pt) 2023-04-11
CL2019000779A1 (es) 2019-07-19
NZ751832A (en) 2024-12-20
US10556957B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
JP7745527B2 (ja) 抗ｓｉｒｐアルファ抗体
JP6727425B2 (ja) 抗ｃｄ２７抗体
JP7379345B2 (ja) 抗ｐｄ－１／ｌａｇ３二重特異性抗体
US12122834B2 (en) Anti-PD-1 antibodies
US20220251194A1 (en) Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bicpecific antibodies
NL2018708B1 (en) ANTI-SIRPα ANTIBODIES
KR20220092569A (ko) 암의 치료를 위한 항-cd27 항체의 투여 요법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190904

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190904

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200331

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200630

R150 Certificate of patent or registration of utility model

Ref document number: 6727425

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250